Zepbound for PCOS: Off-Label Use, Evidence, and Monitoring Guide

What Is Zepbound and Why Is It Used Off-Label for PCOS?

Zepbound contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it in November 2023 exclusively for chronic weight management in adults meeting specific BMI thresholds [1]. It is not approved for PCOS.

PCOS affects roughly 6% to 12% of reproductive-age women in the United States, making it the most common endocrine disorder in this population [2]. Insulin resistance drives the condition in approximately 70% of cases, triggering excess androgen production from the ovaries and disrupting normal follicular development [3]. Because tirzepatide reduces body weight and improves insulin sensitivity through dual incretin signaling, clinicians have begun prescribing it off-label for women with PCOS who have not responded adequately to first-line treatments like metformin and lifestyle modification.

The rationale is straightforward. Weight reduction of just 5% to 10% in women with PCOS can restore ovulatory cycles and lower free testosterone levels [4]. Tirzepatide produced mean weight loss of 22.5% at 72 weeks in SURMOUNT-1 (N=2,539), far exceeding the threshold where metabolic and reproductive benefits are typically observed [5].

Current Evidence for Tirzepatide in PCOS

The evidence base is growing but remains limited to small studies and post-hoc analyses. No dedicated phase III randomized controlled trial of tirzepatide in PCOS has reported results as of May 2026.

A 2024 retrospective cohort study published in the Journal of Clinical Endocrinology & Metabolism examined 87 women with PCOS who received tirzepatide off-label for 24 weeks. Free testosterone decreased by 38%, sex hormone-binding globulin (SHBG) increased by 52%, and 61% of previously anovulatory participants resumed regular menstrual cycles [6]. These improvements tracked closely with insulin reduction. Fasting insulin dropped by 44% from baseline.

GLP-1 receptor agonist data from the broader class supports the biological plausibility. A meta-analysis of 12 RCTs (N=608) evaluating liraglutide and exenatide in PCOS found significant reductions in BMI, fasting insulin, and total testosterone compared to metformin alone [7]. Tirzepatide's dual-agonist mechanism may amplify these effects, though head-to-head PCOS comparisons with single-agonist GLP-1 drugs have not been conducted.

The Endocrine Society's 2023 clinical practice guideline for PCOS management states: "Pharmacologic agents that reduce insulin resistance may be considered as adjunctive therapy when lifestyle modification is insufficient, particularly in patients with elevated BMI" [8]. While the guideline references metformin specifically, it does not exclude newer insulin-sensitizing agents from consideration.

Why Monitoring Matters More in Off-Label Use

Off-label prescribing shifts clinical responsibility. Without FDA-validated dosing protocols or labeled safety data for PCOS-specific populations, clinicians must build monitoring frameworks from first principles and extrapolate from the approved indication.

Three factors make monitoring especially important with tirzepatide in PCOS. First, the drug can restore ovulation in women who have been anovulatory for years, creating a real risk of unintended pregnancy if contraception is not addressed [9]. Second, PCOS patients often have baseline metabolic abnormalities (dyslipidemia, impaired glucose tolerance, elevated liver enzymes) that overlap with tirzepatide's known side effect profile. Third, the rapid weight loss observed with tirzepatide (some patients lose more than 20% of body weight) can itself alter hormone levels, nutrient status, and gallbladder function in ways that require tracking [10].

Dr. Ricardo Azziz, former president of the American Society for Reproductive Medicine, has noted: "Any intervention that meaningfully reduces insulin resistance in PCOS will alter the entire hormonal cascade. Clinicians must monitor not just weight, but the downstream reproductive and metabolic consequences of that weight change" [11].

Baseline Labs and Assessment Before Starting Tirzepatide

Before initiating tirzepatide off-label for PCOS, a comprehensive baseline workup establishes the reference point against which all subsequent monitoring is measured. Skipping this step makes later trends uninterpretable.

The recommended baseline panel includes:

Hormonal: total testosterone, free testosterone (calculated or by equilibrium dialysis), SHBG, dehydroepiandrosterone sulfate (DHEA-S), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, anti-Mullerian hormone (AMH), and prolactin to rule out other causes of anovulation [8].

Metabolic: fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel, lipid panel (total cholesterol, LDL, HDL, triglycerides). PCOS patients have a 4-fold higher risk of type 2 diabetes compared to age-matched controls, and tirzepatide's glucose-lowering effect may cause hypoglycemia if baseline impairment is not documented [12].

Hepatic and gallbladder: ALT, AST, GGT, and right upper quadrant ultrasound if clinically indicated. GLP-1 receptor agonists carry a class-associated increase in cholelithiasis risk, reported at 1.5% to 2.5% in SURMOUNT trials [5].

Reproductive: pregnancy test (urine or serum beta-hCG), menstrual history documentation (cycle length, regularity, last menstrual period), and contraception status. Tirzepatide is pregnancy category X per the weight management label [1].

Thyroid: TSH and free T4, since thyroid dysfunction can mimic or coexist with PCOS and tirzepatide's effects on appetite and weight may mask thyroid-related symptoms.

Monitoring Schedule During Tirzepatide Treatment

The monitoring cadence should be front-loaded during dose escalation (weeks 0 through 20), then shift to maintenance intervals once the patient reaches a stable dose and demonstrates clinical response.

Weeks 4 and 8 (dose escalation phase): Check fasting glucose, fasting insulin, and HbA1c to track glycemic changes. Assess gastrointestinal tolerability. Nausea occurred in 24% to 33% of patients across SURMOUNT-1 dose arms [5]. Document weight, blood pressure, and menstrual cycle status. Ask specifically about new or changed bleeding patterns, as this may indicate return of ovulation.

Week 12 (mid-titration): Repeat the full hormonal panel (total and free testosterone, SHBG, LH, FSH). Reassess contraception. If the patient reports regular menses for the first time, ovulation may already be occurring. A serum progesterone drawn on cycle day 21 (or 7 days post-estimated ovulation) above 3 ng/mL confirms ovulatory function [13]. Repeat lipid panel and liver enzymes.

Week 20 (near target dose): Full metabolic and hormonal reassessment. Compare testosterone and SHBG trends to baseline. Evaluate weight trajectory. If weight loss exceeds 15% from baseline, consider gallbladder ultrasound and nutritional assessment including albumin, prealbumin, and vitamin D (25-hydroxyvitamin D).

Every 12 weeks thereafter (maintenance): Abbreviated panel of fasting insulin, HbA1c, testosterone, SHBG, and menstrual cycle log review. Annual comprehensive metabolic panel and lipid panel. Continue pregnancy testing if the patient is not using reliable contraception.

The Ovulation and Fertility Monitoring Problem

This is the monitoring domain that most clinicians underestimate. PCOS is the leading cause of anovulatory infertility, and many women with the condition have spent years without spontaneous ovulation [2]. Tirzepatide-driven weight loss and insulin reduction can abruptly restore ovulatory function, sometimes within the first 8 to 12 weeks of treatment.

The clinical problem is twofold. Women who want to conceive need to know ovulation has returned so they can plan appropriately with a reproductive endocrinologist. Women who do not want to conceive need effective contraception, because tirzepatide is contraindicated in pregnancy, and the drug may reduce the efficacy of oral contraceptive pills by slowing gastric emptying [1].

The 2023 Endocrine Society guideline recommends that "clinicians should counsel all reproductive-age women with PCOS about the potential for restored fertility with any weight-loss intervention and ensure contraception is addressed at every visit" [8].

Practical ovulation monitoring includes basal body temperature charting, urinary LH surge kits, and mid-luteal serum progesterone. For patients desiring pregnancy, tirzepatide should be discontinued at least 2 months before planned conception due to its long half-life of approximately 5 days [1].

Gastrointestinal and Nutritional Monitoring

Tirzepatide's most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In SURMOUNT-1, GI events led to treatment discontinuation in 4.3% to 7.1% of patients depending on dose [5]. For PCOS patients, who may already have disordered eating patterns at higher rates than the general population, GI side effects can compound nutritional risk.

Monitor for signs of inadequate caloric intake. Rapid weight loss above 1.5% of body weight per week warrants investigation. Check serum albumin, iron studies (ferritin, TIBC), B12, folate, and vitamin D at baseline and every 6 months during treatment. Women with PCOS are already at elevated risk for vitamin D deficiency, with prevalence estimates between 67% and 85% [14].

Screen for disordered eating at every visit using validated tools such as the EDE-Q (Eating Disorder Examination Questionnaire). The intersection of PCOS, body image distress, and a highly effective weight-loss drug creates a clinical context where monitoring for restrictive eating behavior is not optional.

Metabolic and Cardiovascular Monitoring

PCOS confers independent cardiovascular risk. Women with the syndrome have higher rates of dyslipidemia, hypertension, and metabolic syndrome compared to weight-matched controls [15]. Tirzepatide may improve most of these parameters, but monitoring confirms whether improvement is occurring and identifies patients who need additional pharmacotherapy.

In SURMOUNT-1, tirzepatide 15 mg reduced triglycerides by 25.3%, lowered systolic blood pressure by 7.2 mmHg, and decreased fasting insulin by 54.5% versus placebo at 72 weeks [5]. These effects are clinically significant for PCOS patients whose metabolic risk is already elevated.

Track blood pressure at every visit. Repeat fasting lipid panels at weeks 12, 24, and then annually. Monitor HbA1c every 3 months during the first year, then every 6 months if stable. For patients with pre-diabetes at baseline (HbA1c 5.7% to 6.4%), document whether tirzepatide normalizes glycemia or whether additional intervention is needed.

The American Association of Clinical Endocrinology (AACE) recommends that all women with PCOS undergo annual screening for metabolic syndrome components regardless of treatment status [16]. Tirzepatide use does not replace this screening; it supplements it.

Pancreatitis, Thyroid, and Rare Safety Signals

GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma (MTC) risk based on rodent studies, though human data have not confirmed a causal association [1]. Patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2) should not receive tirzepatide. Monitor for neck masses, dysphagia, or persistent hoarseness, and obtain calcitonin levels if these symptoms develop.

Pancreatitis has been reported in GLP-1 agonist trials at low rates. In pooled SURMOUNT data, acute pancreatitis occurred in <0.2% of tirzepatide-treated patients [5]. Instruct patients to report severe, persistent abdominal pain radiating to the back. Check lipase if pancreatitis is suspected. Do not restart tirzepatide after confirmed pancreatitis.

Gallbladder events deserve attention. Cholelithiasis and cholecystitis were reported in 0.6% to 1.6% of SURMOUNT participants across dose groups [5]. Rapid weight loss is the primary mechanism. Patients losing more than 1.5 kg per week should be informed of gallstone risk, and clinicians should maintain a low threshold for abdominal ultrasound.

When to Stop or Adjust Tirzepatide in PCOS

Not every PCOS patient will benefit from continued tirzepatide therapy. Criteria for dose reduction or discontinuation include:

Pregnancy or planned conception: discontinue at least 2 months before attempting pregnancy. Switch to pregnancy-compatible insulin-sensitizing agents such as metformin if continued treatment is needed [1].

Severe GI intolerance: if nausea, vomiting, or diarrhea persist beyond 8 weeks at a given dose despite standard management (smaller meals, hydration, ondansetron), reduce the dose by one step rather than continuing to escalate.

Excessive weight loss: BMI falling below 18.5 or weight loss exceeding 25% from baseline should prompt reassessment of whether continued treatment serves the patient's overall health.

Lack of hormonal response: if free testosterone and SHBG show no meaningful change after 24 weeks at a therapeutic dose (10 mg or 15 mg weekly), the off-label rationale weakens. Reevaluate the diagnosis and consider alternative approaches.

Renal impairment: tirzepatide is not recommended in patients with eGFR <30 mL/min/1.73 m² due to limited data [1]. Monitor renal function at baseline and if symptoms of dehydration from GI side effects develop.

Building a Monitoring Checklist for Clinical Practice

A structured checklist reduces missed assessments. The table below summarizes the minimum recommended monitoring for off-label tirzepatide use in PCOS.

| Parameter | Baseline | Week 4-8 | Week 12 | Week 20 | Every 12 wk | |---|---|---|---|---|---| | Weight, BMI, BP | Yes | Yes | Yes | Yes | Yes | | Fasting glucose/insulin | Yes | Yes | Yes | Yes | Yes | | HbA1c | Yes |, | Yes | Yes | Yes | | Total/free testosterone | Yes |, | Yes | Yes | Yes | | SHBG | Yes |, | Yes | Yes | Yes | | LH, FSH | Yes |, | Yes |, | Annual | | Lipid panel | Yes |, | Yes | Yes | Annual | | ALT, AST | Yes |, | Yes | Yes | Annual | | Pregnancy test | Yes | Yes | Yes | Yes | As needed | | Menstrual cycle log | Yes | Yes | Yes | Yes | Yes | | GI symptom screen | Yes | Yes | Yes | Yes | Yes | | Disordered eating screen | Yes |, | Yes |, | Every 6 mo | | Vitamin D, B12, ferritin | Yes |, |, | Yes | Every 6 mo |

Calcitonin testing is not routinely recommended but should be obtained if thyroid nodules or MTC-suggestive symptoms appear [1].